Buy & Sell Oklo Inc (OKLO) – Oklo Inc Price Today
Aura AI Summary
Key Stats
- $9.72BMarket Cap
- TechnologySector
- -34.01%3M Drawdown
- $7.52BEnterprise Value
- -Dividend Yield
- 46% Buy | 54% SellTrading Activity
- 10 daysTypical Hold Time
Oklo Inc (OKLO) is currently valued at a market capitalization of $9.72B, with an enterprise value of $7.52B. Over the past 52 weeks, Oklo Inc has traded between a low of $36.81 and a high of $174.14, highlighting its annual price range. Over the past three months, Oklo Inc has recorded a drawdown of -34.01%, reflecting recent price volatility. On average, investors hold Oklo Inc for approximately 10 days, indicating typical investor behavior on the platform.
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Most Recent News
State Street Global Advisors buys 3,532 shares in DCC plc, raising stake to 1.39%
State Street Global Advisors & Affiliates purchased 3,532 ordinary shares of DCC plc on May 19, 2026, at a price of €59.90 per share. This transaction increased their total holding to 1,189,358 shares, representing 1.3923% of the company's shares. Th...

Stellantis plans Europe JV to sell Dongfeng EVs, plus new affordable EV launch in 2028.
Stellantis and Dongfeng signed a non-binding Memorandum of Understanding to create a Europe-based joint venture focused on sales, distribution, and engineering of Dongfeng's new energy vehicles (NEVs). The JV, majority-owned by Stellantis, will launc...

Cell-based therapies advance with Avaí Bio's α-Klotho cell bank milestone, boosting anti-aging and neurodegenerative treatment prospects.
Avaí Bio and Austrianova have completed a Master Cell Bank of genetically modified cells overexpressing the α-Klotho protein, a key anti-aging factor, marking a major step toward clinical trials for cell-based therapies targeting aging and related di...
